Drug intelligence / Profile preview

Yinaokang

Development stage: Unknown
Lead developer: Guangdong Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Yinaokang is a Traditional Chinese Medicine (TCM) herbal capsule developed by the Guangdong Provincial Hospital of Chinese Medicine. It is primarily indicated for post-stroke cognitive impairment no dementia (PSCIND), a condition where patients exhibit cognitive decline following a stroke that is not severe enough to be classified as dementia. The formula is designed to improve cognitive performance and support neurological recovery. As a multi-herb preparation, its mechanism of action involves synergistic effects on cerebral blood flow, neuroinflammation, and neuronal protection. It has been the subject of clinical investigation in China to evaluate its therapeutic efficacy and safety profile.

Brand names: Yinaokang
Other names: Yi-nao-kangYinaokang capsule

Beyond the preview

Go deeper on Yinaokang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yinaokang.

Explore the full profile